Synthesis of cleavable fluorescent nucleotides as reversible terminators for DNA sequencing by synthesis
US-9175342-B2 · Nov 3, 2015 · US
US9933431B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9933431-B2 |
| Application number | US-201514820875-A |
| Country | US |
| Kind code | B2 |
| Filing date | Aug 7, 2015 |
| Priority date | Aug 22, 2014 |
| Publication date | Apr 3, 2018 |
| Grant date | Apr 3, 2018 |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
A system for the iterative detection of biological molecules includes a probe, and a fluorophore tethered to the probe with an azide-based linker. The linker is configured to be cleaved in the presence of tris(2-carboxyethyl)phosphine (TCEP), and the on/off ratio between a signal measured before treatment with TCEP and a signal measured after treatment with TCEP is at least about 20:1.
Opening claim text (preview).
What is claimed is: 1. A system for iterative in situ fluorescence detection of biological molecules, comprising: a multi-nucleotide or antibody probe; and a fluorophore tethered to the probe by an azide-based linker; wherein the azide-based linker is configured to be cleaved by tris(2-carboxyethyl)phosphine (TCEP) at a plurality of sequential TCEP-specific cleavage sites within said linker thereby cleaving the fluorophore from the multi-nucleotide or antibody probe upon exposure to TCEP, and wherein the on/off ratio between a fluorescent signal produced by said fluorophore measured before treatment with TCEP and a fluorescent signal produced by said fluorophore measured after treatment with TCEP is at least about 20:1. 2. The system of claim 1 , wherein the linker is: wherein R 1 is linkage between one of the probe and the fluorophore and wherein R 2 is a linkage between the other of the probe and the fluorophore. 3. The system of claim 1 , wherein the multi-nucleotide or antibody probe is selected for the detection of at least one of a DNA target, an RNA target, a protein target and a small molecule target. 4. A method for iterative in situ fluorescence detection a biological molecule, comprising: incubating a sample including a target molecule with a detection system, the detection system including a multi-nucleotide or antibody probe and a fluorophore tethered to the probe by an azide-based linker comprising a plurality of TCEP-specific cleavage sites; exciting the incubated sample at a first wavelength; detecting the emission of a second wavelength from the excited, incubated sample; and contacting tris(2-carboxyethyl)phosphine (TCEP) to the excited, incubated sample, whereby the TCEP cleaves at one or more of the plurality of sequential TCEP-specific cleavage sites, thereby cleaving the fluorophore from the probe, wherein the on/off ratio between the emission of the second wavelength detected before the contacting step and an emission of the second wavelength after the contacting step is at least about 20:1. 5. The method of claim 4 , further including, repeating the steps of incubating, exciting and detecting. 6. The method of claim 4 , wherein the linker is: wherein R 1 is linkage between one of the probe and the fluorophore and wherein R 2 is a linkage between the other of the probe and the fluorophore. 7. The method of claim 4 , wherein the probe is selected for the in situ detection of at least one of a DNA target, an RNA target, a protein target and a small molecule target. 8. The method of claim 4 , further including binding the target molecule with the probe. 9. The method of claim 4 , wherein the on/off ratio between a signal measured before treatment with TCEP and a signal measured after treatment with TCEP is at least about 50:1.
with fluorescent label · CPC title
Release of bound markers · CPC title
fluorescence · CPC title
Specific component of sample, medium or buffer · CPC title
Related publications grouped by family.
Answers are generated from the same data shown on this page.